Michael Voulgarelis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6959323/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Risk of Lymphoma Development in Autoimmune Diseases. Archives of Internal Medicine, 2005, 165, 2337.	3.8	647
2	Hematologic Manifestations and Predictors of Lymphoma Development in Primary Sjögren Syndrome. Medicine (United States), 2009, 88, 284-293.	1.0	233
3	Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. Journal of Autoimmunity, 2015, 63, 47-58.	6.5	215
4	Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nature Reviews Rheumatology, 2010, 6, 529-537.	8.0	206
5	Prognosis and Outcome of Non-Hodgkin Lymphoma in Primary Sjögren Syndrome. Medicine (United) Tj ETQq1 I	1 9.78431	4 rgBT /Ove
6	Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes. Clinical Cancer Research, 2007, 13, 1154-1160.	7.0	124
7	B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. Journal of Autoimmunity, 2014, 51, 89-98.	6.5	99
8	Myelodysplasiaâ€associated autoimmunity: clinical and pathophysiologic concepts. European Journal of Clinical Investigation, 2004, 34, 690-700.	3.4	84
9	Predicting the Outcome of Sjogren's Syndrome-Associated Non-Hodgkin's Lymphoma Patients. PLoS ONE, 2015, 10, e0116189.	2.5	77
10	Mucosa-Associated Lymphoid Tissue Lymphoma in Sjögren's Syndrome: Risks, Management, and Prognosis. Rheumatic Disease Clinics of North America, 2008, 34, 921-933.	1.9	69
11	Clinical picture, outcome and predictive factors of lymphoma in SjÓ§gren syndrome. Autoimmunity Reviews, 2015, 14, 641-649.	5.8	68
12	Bone marrow histological findings in systemic lupus erythematosus with hematologic abnormalities: A clinicopathological study. American Journal of Hematology, 2006, 81, 590-597.	4.1	67
13	Clinical, Immunologic, and Molecular Factors Predicting Lymphoma Development in Sjogren's Syndrome Patients. Clinical Reviews in Allergy and Immunology, 2007, 32, 265-274.	6.5	67
14	Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology, 2014, 53, 2209-2213.	1.9	67
15	Malignant lymphoma in primary Sjögren's syndrome: An update on the pathogenesis and treatment. Seminars in Arthritis and Rheumatism, 2013, 43, 178-186.	3.4	63
16	A BAFF Receptor His159Tyr Mutation in Sjögren's Syndrome–Related Lymphoproliferation. Arthritis and Rheumatology, 2015, 67, 2732-2741.	5.6	60
17	Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica, 2015, 100, e446-e449.	3.5	44
18	Suspects in the tale of lupus-associated thrombocytopenia. Clinical and Experimental Immunology, 2006, 145, 71-80.	2.6	40

MICHAEL VOULGARELIS

#	Article	IF	CITATIONS
19	Predictive markers of lymphomagenesis in Sj¶gren's syndrome: From clinical data to molecular stratification. Journal of Autoimmunity, 2019, 104, 102316.	6.5	36
20	Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with SjŶgren's syndrome. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212639.	0.9	32
21	Current aspects of pathogenesis in Sjögren's syndrome. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 325-334.	2.7	31
22	MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome. Scientific Reports, 2017, 7, 7354.	3.3	28
23	Predicting progression to lymphoma in Sjögren's syndrome patients. Expert Review of Clinical Immunology, 2014, 10, 501-512.	3.0	26
24	Autoimmune manifestations in common variable immunodeficiency. Clinical Rheumatology, 2004, 23, 449-452.	2.2	25
25	Effect of cA2 Anti–Tumor Necrosis Factor-α Antibody Therapy on Hematopoiesis of Patients with Myelodysplastic Syndromes. Clinical Cancer Research, 2006, 12, 3099-3108.	7.0	24
26	TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients. Journal of Immunology Research, 2018, 2018, 1-8.	2.2	24
27	Clinical picture, outcome and predictive factors of lymphoma in primary Sjögren's syndrome: results from a harmonized dataset (1981–2021). Rheumatology, 2022, 61, 3576-3585.	1.9	19
28	Myelofibrosis-associated massive splenomegaly: A cause of increased intra-abdominal pressure, pulmonary hypertension, and positional dyspnea. American Journal of Hematology, 2005, 80, 128-132.	4.1	18
29	TREX1 variants in Sjogren's syndrome related lymphomagenesis. Cytokine, 2020, 132, 154781.	3.2	18
30	Effects of Visceralising Leishmania on the Spleen, Liver, and Bone Marrow: A Pathophysiological Perspective. Microorganisms, 2021, 9, 759.	3.6	18
31	Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells. Leukemia Research, 2006, 30, 1177-1186.	0.8	17
32	<i>CSTT1</i> and <i>GSTM1</i> polymorphisms and myelodysplastic syndrome risk: a systematic review and metaâ€analysis. International Journal of Cancer, 2010, 126, 1716-1723.	5.1	17
33	Aplastic anemia associated with interferon alpha 2a in a patient with chronic hepatitis C virus infection: a case report. Journal of Medical Case Reports, 2010, 4, 268.	0.8	17
34	Membranous glomerulonephritis in chronic lymphocytic leukemia. American Journal of Hematology, 2004, 76, 271-274.	4.1	16
35	Pathogenetic Mechanisms Implicated in Sjögren's Syndrome Lymphomagenesis: A Review of the Literature. Journal of Clinical Medicine, 2020, 9, 3794.	2.4	16
36	RNA Interference of Interferon Regulatory Factor-1 Gene Expression in THP-1 Cell Line Leads to Toll-Like Receptor-4 Overexpression/Activation As Well As Up-modulation of Annexin-II. Neoplasia, 2007, 9, 1012-1020.	5.3	15

#	Article	IF	CITATIONS
37	Simultaneous occurrence of pure red cell aplasia and papular-purpuric 'gloves and socks' syndrome in parvovirus B-19 infection. Journal of the European Academy of Dermatology and Venereology, 2005, 19, 373-376.	2.4	10
38	GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34+ and erythroid CD71+ cells in myelodysplastic syndromes. American Journal of Hematology, 2007, 82, 887-892.	4.1	10
39	A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases. Expert Review of Clinical Immunology, 2014, 10, 1679-1688.	3.0	9
40	Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts. Cancers, 2020, 12, 3520.	3.7	9
41	Interferon (IFN)-stimulated gene 15: A novel biomarker for lymphoma development in Sjögren's syndrome. Journal of Autoimmunity, 2021, 123, 102704.	6.5	9
42	Serum, but Not Saliva, CXCL13 Levels Associate With Infiltrating CXCL13+ Cells in the Minor Salivary Gland Lesions and Other Histologic Parameters in Patients With Sjögren's Syndrome. Frontiers in Immunology, 2021, 12, 705079.	4.8	8
43	Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjogren's Syndrome. Journal of Clinical Medicine, 2021, 10, 644.	2.4	7
44	Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?. Frontiers in Immunology, 2021, 12, 683623.	4.8	6
45	From the (Epi)Genome to Metabolism and Vice Versa; Examples from Hematologic Malignancy. International Journal of Molecular Sciences, 2021, 22, 6321.	4.1	5
46	+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with SjĶgren's Syndrome: Potential Clinical and Pathogenetic Implications. Journal of Clinical Medicine, 2021, 10, 3960.	2.4	5
47	Lymphoma Severity and Type Are Associated With Aortic FDG Uptake by 18F-FDG PET/CT Imaging. JACC: CardioOncology, 2020, 2, 758-770.	4.0	5
48	Bone marrow necrosis and fat embolism syndrome presented as conus medullaris syndrome in a patient with primary mediastinal large B-cell lymphoma. Leukemia Research, 2010, 34, 116-118.	0.8	4
49	Autophagy in Myelodysplastic Syndromes: The Role of HIF-1a/REDD1 Molecular Pathway. Blood, 2018, 132, 1808-1808.	1.4	4
50	Leishmaniasis with cryoglobulinaemia and <i>Leishmania infantum</i> in peripheral blood neutrophils. British Journal of Haematology, 2020, 189, 801-801.	2.5	3
51	Exploiting the Role of Hypoxia-Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology. International Journal of Molecular Sciences, 2021, 22, 4099.	4.1	3
52	Extraordinary extrahaematological manifestations of chronic myelomonocytic leukaemia. Lancet, The, 2020, 396, 853.	13.7	2
53	Inheritance and Myelodysplasia progression. Leukemia Research, 2013, 37, 1185-1186.	0.8	1
54	The Metabolomic Status of the Differentiating Myeloid Lineage in MDS with Low and High Bone Marrow Blast Counts. Blood, 2020, 136, 32-33.	1.4	1

MICHAEL VOULGARELIS

#	Article	IF	CITATIONS
55	Akt Signaling Pathway Is Activated in the Minor Salivary Glands of Patients with Primary Sjögren's Syndrome. International Journal of Molecular Sciences, 2021, 22, 13441.	4.1	1
56	07.08â€Contribution of mthfr gene polymorphisms in primary sjögren's syndrome related lymphomagenesis. , 2017, , .		0
57	08.16â€Mir200B-5p expression in minor salivary glands (msg): a possible predictor of lymphoma development in sjögren's syndrome (ss). , 2017, , .		0
58	Response to: â€~ls miR200b-5p a new predictor of lymphoma or associated with lymphocytes infiltrate within salivary glands?' by Nocturne et al. Annals of the Rheumatic Diseases, 2019, 78, e96-e96.	0.9	0
59	AB0527â€PREDICTIVE VALUE OF MIR200B-5P IN THE LYMPHOMAGENESIS IN SJÖGREN'S SYNDROME (SS COMPARISON WITH THE PUBLISHED PREDICTION MODELS. PRELIMINARY RESULTS. , 2019, , .):	0
60	SATO190â€LYMPHOMA IN PRIMARY SJÖGREN'S SYNDROME: A RETROSPECTIVE CLINICAL STUDY WITH PA FROM THE UPA (UDINE, PISA, ATHENS) GROUP. , 2019, , .	ATIENTS	0
61	No Evidence for Increased Prevalence of JAK2 V617F in Women with a History of Recurrent Miscarriage. Blood, 2008, 112, 5235-5235.	1.4	0
62	Cardiac Magnetic Resonance Imaging Detects Long-Term Fibrotic Changes in Patients with Primary Eosinophilic Disorders: A Cross-Sectional Study. Blood, 2008, 112, 5236-5236.	1.4	0